Ahmad El Ouweini, Pharm.D., BCPS, FCPR-CC’s Post

Ozempic Gains FDA Approval for Chronic Kidney Disease Treatment in Diabetics : The FDA has approved Novo Nordisk’s Ozempic to treat chronic kidney disease in people with Type 2 diabetes, expanding its use beyond diabetes management. A major study showed Ozempic can slow kidney decline, lower the risk of heart-related deaths, and reduce severe kidney complications by 24%. This approval highlights the broader health benefits of GLP-1 drugs like Ozempic, which are already used for diabetes and weight loss, while Novo Nordisk faces growing competition and ongoing Medicare drug price negotiations. Read more: https://lnkd.in/d8hQYpbp #fdaapproval #fda #ozempic #nephrology #medicalresearch #clinicalresearch #medicalupdate #medicalupdates #medicalnews #pharmaupdate #pharmaupdates #pharmanews #healthcareupdate #healthcareupdates #healthcarenews #hcp #scientificupdate #clinicalguideline #clinicalguidelines #medicalguideline #medicalguidelines #carbonbrandsolutions

𝐋𝐢𝐥𝐥𝐲 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥𝐬 𝐨𝐟 𝐎𝐧𝐜𝐞-𝐖𝐞𝐞𝐤𝐥𝐲 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 𝐄𝐟𝐬𝐢𝐭𝐨𝐫𝐚 Lilly Eli Lilly and Company has revealed positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once-weekly insulin efsitora in adults with type 2 diabetes. These trials demonstrated non-inferior A1C reduction compared to daily basal insulins, indicating the potential to simplify diabetes management. Efsitora, delivered through a simple fixed-dose regimen, could make insulin therapy more manageable and reduce the burden on patients. QWINT-1 and QWINT-3 trials showed efsitora achieved significant A1C reduction in insulin-naïve patients and those switching from daily basal insulin injections. The safety profile of efsitora was similar to that of daily basal insulins, with reduced rates of severe hypoglycemia. Detailed results will be shared at future congresses. #DiabetesCare #Type2Diabetes #InsulinInnovation #PharmaNews #ClinicalTrials #DiabetesManagement #Efsitora #Lilly

Wegovy—Novo Nordisk, is now the first weight-loss medication to also win FDA approval as an intervention for lowering cardiovascular (CV) risk in adults with obesity or overweight. The findings showed that Wegovy reduced the risk of stroke, heart attack, and other CV problems by 20% in this population. Semaglutide, which is also the active ingredient in Novo's diabetes drug Ozempic, works by delaying emptying of the stomach — which has the effect of suppressed appetite in users. While FDA's decision raises hope that more insurers will cover Wegovy for more patients, effectively bringing production up to meet demand and driving prices down are still challenges. https://lnkd.in/ePvvr8-H

#Semaglutide (Ozempic and Wegovy): Uses, Mechanism, and Potential Implications for Contraceptive Effectiveness #Semaglutide (marketed as Ozempic and Wegovy) is a medication primarily used to manage type 2 diabetes. It functions as a GLP-1 receptor agonist, which helps regulate blood sugar levels by stimulating insulin secretion and inhibiting glucagon release. #Recent_Applications_and_Mechanisms_of_Action Recently, semaglutide has garnered attention for its efficacy in promoting weight loss. The drug operates by: - Slowing gastric emptying. - Reducing appetite. - Increasing feelings of fullness. #Clinical_Efficacy Clinical trials have demonstrated that semaglutide can result in significant weight loss for individuals both with and without type 2 diabetes. #Dosage_for_Weight_Loss: The typical starting dose is 0.25 mg once weekly, with a gradual increase to 1 mg once weekly. For weight loss, higher doses, up to 2.4 mg weekly, have been studied. #Interaction_with_Oral_Contraceptives A noteworthy consideration is the potential interaction between semaglutide and oral contraceptives. Recent studies suggest that semaglutide may impact the absorption of oral contraceptives due to its effect on gastric emptying. This delayed gastric emptying may lead to lower plasma concentrations of contraceptives, potentially reducing their effectiveness. There have been reports, particularly among women with PCOS, of pregnancies occurring while using both Ozempic and oral contraceptives. This raises concerns about the reliability of oral contraceptives when used concurrently with semaglutide. #Conclusion If you are considering using Ozempic for weight loss or have concerns regarding its interactions with oral contraceptives, it is essential to consult with your prescribing physician to evaluate the risks and make informed decisions. #Sources: Clinical trials and studies on semaglutide vs weight loss.

On #WorldHypertensionDay, Lyrus, a leading pharmaceutical Contract Development and Manufacturing Organization (CDMO), would like to raise awareness about the global burden of #hypertension, also known as high blood pressure. Hypertension is a major risk factor for cardiovascular diseases, such as heart attacks, strokes, and heart failure, which are among the leading causes of death worldwide. According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30-79 years worldwide have hypertension. At Lyrus, we recognize the critical importance of addressing this global health challenge. Through our comprehensive range of services, including formulation development and manufacturing, we are committed to supporting our pharmaceutical partners in developing innovative and effective treatments for hypertension and its associated complications. Our team of experts collaborates closely with our clients, leveraging our state-of-the-art facilities and cutting-edge technologies to advance the development of antihypertensive medications. From development to commercial manufacturing, we ensure strict adherence to quality standards and regulatory guidelines. Furthermore, we understand the importance of patient-centric approaches in managing hypertension. Our expertise in formulation development and drug delivery systems enables us to contribute to improved patient adherence and better treatment outcomes. On this World Hypertension Day, Lyrus reaffirms its commitment to supporting the global healthcare community in addressing this silent killer. Together, we can raise awareness, promote early detection, and facilitate access to effective treatments, ultimately improving the lives of millions of people affected by hypertension worldwide. #WorldHypertensionDay #RaisingAwareness #InnovativeTherapies #PatientCentricApproaches #CDMO #ThinkDesignDeliver #Lyrus  C P Bothra Hemanth bothra Rajesh Goel Elayaraja Natarajan Ramdas Velliyate Jyolsna Agnes Jose Krishna M S Raviraj Kadam

✅ Wegovy (semaglutide): 🔶 Another new indication for Wegovy? 🔶 Novo Nordisk’s blockbuster GLP-1 drug improved symptoms and physical function in a trial of patients with: ✔️ obesity ✔️diabetes ✔️and heart failure with preserved ejection fraction. ✅ This comes after Novo reported positive results last year in a similar HFpEF trial, but in patients😳👉 who didn't have diabetes. ✅ With the data from these two new trials, Novo is now seeking regulatory approval for a new indication for Wegovy in HFpEF. 🛜 The drug is quickly amassing data that shows its benefits beyond weight loss. 🛜 It just last month 👉got FDA clearance for the use of preventing cardiovascular complications. #Dose_of_Knowledge

OTC proton pump inhibitors (PPIs), highlighting their dual role in providing convenient relief for acid-related issues while also posing risks of overuse and potential long-term side effects. This underscores the importance of balancing accessibility with proper usage guidance. As healthcare professionals, it's crucial to promote informed decisions through patient education to maximize benefits and minimize risks. https://lnkd.in/gtg2rf3T

📌 Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. 📌 This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/ EZE as single-pill combination in the setting of real clinical practice in Italy. 📌 In a dyslipidemic population previously treated with ROS/EZE as free pill combination, the proportion of adherent patients significantly increased (from 51.8% to 75.1%) after switching to single-pill combination. 📌 These findings confirm that simplifying lipid- lowering therapy through single-pill combination of ROS/EZE represents a valid strategy to improve medication adherence, which is essential for increasing the likelihood of reaching the recommended LDL-C targets to improve cardiovascular outcomes, with the ultimate goal of alleviating the clinical and economic burden related to ASCVD. #Adherence #Rosuvastatin #Ezetimibe #SinglePillCombination #RealWorldEvidence Follow-us CliCon S.r.l. Società Benefit

#Efsitora from Eli Lilly and Company produced a mean reduction in HbA1c from 7.88% at baseline to 7.41% by 26 weeks (normal range for HbA1c is between 4% and 5.6%), or halfway through the trial. At the same time point, #degludec had reduced HbA1c from 7.94% to 7.36%. in this study, results showed that, for type 2 diabetics, efsitora was non-inferior to degludec concerning the change in HbA1c in participants who were taking GLP-1s as well as those who weren’t. The time that participants spent in their target blood sugar range (‘time in range’) was 64.3% with efsitora and 61.2% with degludec. No episodes of severe hypoglycemia were reported with efsitora; six were reported with degludec

⚕️Monthly Drug Safety 💊 Beta- lockers (Metoprolol, Propranolol ,Atenolol) Beta-blockers (Metoprolol, Propranolol, Atenolol) Metoprolol: For the treatment of essential hypertension in adults, functional heart disorders, migraine prophylaxis, cardiac arrhythmias, prevention of cardiac death and reinfarction after the acute phase of myocardial infarction, stable symptomatic CHF and angina pectoris. Propranolol: For the treatment of cardiac arrhythmias; tachycardia; hypertrophic obstructive cardiac myopathy; pheochromocytoma; thrombosis; management of angina; essential and renal hypertension; prophylaxis of migraine. Atenolol: For the treatment of hypertension, angina pectoris, cardiac arrhythmias. Adverse effect: Hypokalaemia)